Canagliflozin Alternatives in Oklahoma
Compare generic and therapeutic alternatives to Canagliflozin (canagliflozin) available at Oklahoma pharmacies. Save up to 48% on your prescription — no insurance required.
Top Alternatives in Oklahoma
Metformin
therapeutic
First-line T2D medication — dramatically cheaper
Avg cash price: $8/mo
Dapagliflozin (Farxiga)
therapeutic
Competing SGLT2 inhibitor with similar profile
Avg cash price: $530/mo
Empagliflozin (Jardiance)
therapeutic
SGLT2 inhibitor with strong cardiovascular outcomes data
Avg cash price: $560/mo
Oklahoma Prescription Assistance Programs
Oklahoma Medicaid (SoonerCare)
Prescription drug coverage for SoonerCare (Oklahoma Medicaid) beneficiaries through managed care organizations.
Eligibility: Low-income Oklahoma adults (expanded Medicaid under SQ802 in 2021), children, pregnant women, and people with disabilities.
Frequently Asked Questions
Is there a generic for canagliflozin (Invokana)?
Not yet as of 2025. Canagliflozin is still under brand exclusivity as Invokana. All SGLT2 inhibitors remain brand-only at similar high prices.
How does canagliflozin compare to other SGLT2 inhibitors?
Canagliflozin, dapagliflozin, and empagliflozin have similar glucose-lowering effects. Differences emerge in cardiovascular and renal outcomes data — your cardiologist or endocrinologist guides the choice.
What is the main risk specific to canagliflozin?
Canagliflozin carries an FDA warning about increased risk of lower-limb amputations, particularly in patients with peripheral vascular disease. Discuss your individual risk with your doctor.
Can Script Unlock help with canagliflozin costs?
While there is no generic, Script Unlock pharmacies sometimes offer lower cash-pay brand pricing. It is worth posting your script to compare bids.
Is metformin a good alternative to canagliflozin for T2D?
Metformin is first-line T2D therapy at under $10/month. SGLT2 inhibitors like canagliflozin are added for patients who need additional cardiovascular or renal benefits beyond glucose lowering.